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The Problem
Managing patients with OP requiring spine surgery is a
challenge because
1. Difficulty in instrumentation
2. Concern for nonunion/non-healing
3. Adjacent level fracture
There are animal studies regarding medication treatment,
graft incorporation and fusion
However, only limited human clinical evidence

Objectives
• Review current data on bisphosphonate (BP) use
in patients with OP undergoing spine surgery
• Review current data on anabolic therapy use in
patients with OP undergoing spine surgery
• Deduce what would be reasonable treatment
options based on the best available data

Drug Therapies
• Oral & IV Bisphosphonates
• Anabolic therapies
– Teriparatide
– Abaloparatide

Bone Physiology

Drug Therapies
• Bisphosphonates
1) Anti-fracture effect
2) Reduction in morbidity
3) Reduced health-care costs
4) Reduced mortality

Bisphosphonates
Previous studies using animal models suggested
that bisphosphonates show negative effects on
spinal fusion

• Retrospective study
• 44 patients with symptomatic degenerative lumbar
spinal stenosis
• 1-2 level fusion
• IV Zoledronic acid 2 weeks after surgery

Divided into 4 groups:
•
•
•
•

Group 1: autograft and zoledronic acid
Group 2: allograft/autograft and zoledronic acid
Group 3: autograft alone
Group 4: allograft/autograft

Radiography and 3D CT used to evaluate and
quantify the volume of the fusion-mass

Results/Conclusion
• Most patients showed bone union at 6
months after surgery
• There were no significant differences in fusion
rates among the 4-groups
• A single dose of zoledronic acid does not
decrease the volume of the fusion-mass in
patients with OP undergoing spinal fusion

Results
• Grade A or B bridging bone was more frequently observed
in zoledronic acid group at 3, 6, and 9 months postoperation compared to the control group (p < 0.05)
• At 12-months there was no significantly difference between
groups
• No patients in zoledronic acid group showed adjacent
vertebral compression fractures (VCF), whereas 6 patients
(17%) in the control group did (p < 0.05)
• Zoledronic acid prevented immobilization induced bone
loss in the hip (BMD data)

Conclusions
Treatment with zoledronic acid in osteoporotic
patients with spinal fusion
1. Shortens the time to fusion
2. Improves the fusion rate
3. Prevents subsequent aVCFs

Drug Therapies
Anabolic therapy: Teriparatide/abaloparatide
1) Builds new bone
2) Significantly reduces the risk of subsequent
vertebral and nonvertebral fragility fractures
in patients with OP

3) Improve both spine and hip BMD quickly &

robustly

Teriparatide Accelerates Spine Surgery
Fusion in Women with Osteoporosis
• 57 postmenopausal women had spinal
decompression at 1 or 2 levels
• 29 received teriparatide 20 mcg/d and 28
received risedronate 17.5 mg weekly
• Medication was started 2 months prior to
surgery and continued 8 months post surgery

Teriparatide Accelerates Spine Surgery
Fusion in Women with Osteoporosis
• The rate of bone union was 82% in the
teriparatide group and 68% in the
bisphosphonate group
• Average duration of bone union was 8 months
in the teriparatide group and 10 months in the
bisphosphonate group

Teriparatide Accelerates Spine Surgery
Fusion in Women with Osteoporosis
• Conclusion: The rate of bone union in the
teriparatide group patients were signiﬁcantly
better than in the bisphosphonate group
• Bone union: defined as bridging bone formation
across the transverse process between adjacent
vertebrae ( CT done at 6 and 12 mo)

Pedicle Screw (PS) Loosening After
Lumbar Spinal Fusion Surgery
• 62 women with osteoporosis had spinal fusion at 1-2 levels
• Drugs were started 2 mo prior to surgery and continued for
10 mo after surgery with 12 mo F/U

•
•
•
•

PS Loosening
13% in the teriparatide group had PS loosening
26% in the risedronate group
25% in the control group
PS loosening was significantly lower in teriparatide group
compared to risedronate or control group ( P < 0.05).

Conclusion
• This study suggests that anabolic therapy with
teriparatide increased the quality of the
lumbar spine bone and pedicle cortex.

Study Conclusion
Teriparatide 20 mcg dose significantly shortened
the median time to healing compared to
placebo.

Conclusion: Effects of Drugs in Spine
Fusion
• A single dose of zoledronic acid does not
decrease the volume of the fusion-mass in
patients with OP undergoing spinal fusion
• Less screw loosening with teriparatide
• Teriparatide speeds up fusion ( healing based
on distal radial fracture data)

So which patients should we consider?
• Severe osteoporosis
• If spine surgery can be delayed for 2-3 months
• Remodeling based patient selection
– TPTD or Abaloparatide if low (Serum CTX <200)
– BPs if high (Serum CTX >500)

• Patient without contra-indications for BPs or
anabolic therapy
– Paget’s disease of bone, Hypercalcemia, prior
radiation to the skelton etc.
– GI intolerance, renal dysfunction etc for BPs

Team Work
• Multidisciplinary approach
• Spine surgeon, Endocrinologist, PCP

